Praluent (Alirocumab) and Sexual Function: What the Evidence Actually Shows

Why This Question Matters Clinically

Sexual dysfunction is a common reason patients discontinue cardiovascular medications. Roughly 25% of men who stop statin therapy cite sexual side effects as a contributing factor, even though the causal evidence for statins is contested 1. When alirocumab is added to a statin regimen, patients and clinicians reasonably ask whether the new agent adds to that risk or perhaps changes it in either direction. Cholesterol is the obligate precursor to all steroid hormones, including testosterone, estradiol, and progesterone 2. Any drug that dramatically lowers circulating cholesterol could, in theory, influence the substrate available for gonadal steroidogenesis.

The Steroidogenesis Concern in Brief

The adrenal cortex and gonads synthesize sex hormones from cholesterol delivered primarily by LDL receptors and, to a lesser extent, by scavenger receptors 3. PCSK9 inhibition upregulates hepatic LDL receptors, pulling more LDL-C out of circulation. Whether peripheral steroidogenic tissues experience a meaningful cholesterol deficit at the doses used clinically is the central mechanistic question. Short answer: probably not, for reasons explained in the sections below.

What Patients Are Actually Asking

Most patient concerns fall into three categories: reduced libido, erectile dysfunction in men, and menstrual or vaginal changes in women. None of these endpoints appeared as pre-specified outcomes in the ODYSSEY OUTCOMES trial 4. That absence is both a limitation of the data and a reflection of the fact that no early-phase signal prompted investigators to track them prospectively.

PCSK9 Biology and the Cholesterol-Hormone Axis

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted primarily by hepatocytes. Its job is to escort LDL receptors toward lysosomal degradation rather than allowing them to recycle to the cell surface 5. Alirocumab binds PCSK9 in plasma, preventing receptor binding and degradation. More LDL receptors survive on hepatocyte surfaces, more LDL-C is cleared, and plasma LDL-C falls by roughly 50 to 60% on top of statin therapy 6.

PCSK9 Expression in Steroidogenic Tissues

PCSK9 is not expressed exclusively in the liver. Gene-expression databases and human tissue studies confirm PCSK9 mRNA in the adrenal gland, testis, and ovary 7. This local expression suggests the enzyme may regulate cholesterol availability within steroidogenic cells themselves, not just hepatic clearance of circulating LDL. A 2017 study by Norata and colleagues found that PCSK9 loss-of-function variants in humans were associated with slightly higher adrenal androgen levels, which runs counter to the concern that PCSK9 inhibition would deplete sex-hormone precursors 7.

Cellular Cholesterol Supply for Steroid Synthesis

Steroidogenic cells meet their cholesterol needs through multiple redundant pathways: LDL receptor-mediated uptake, HDL-mediated selective uptake via SR-BI, de novo synthesis via the mevalonate pathway, and mobilization of intracellular cholesteryl ester stores 8. This redundancy is the key safety argument. Even when circulating LDL-C is reduced to 20 to 30 mg/dL by combined statin plus PCSK9 inhibitor therapy, cells retain multiple alternative cholesterol sources. Animal studies in PCSK9-knockout mice show normal reproductive function and gonadal steroidogenesis 9.

Plasma LDL-C Thresholds and Hormone Synthesis

A 2019 analysis of the FOURIER trial (evolocumab, N=27,564) examined sex-hormone binding globulin and free testosterone in a subset of male participants 10. Median LDL-C in the evolocumab arm fell to 30 mg/dL. No significant difference in free testosterone emerged between evolocumab and placebo at 12 months. Alirocumab is the same mechanistic drug class; no published alirocumab-specific hormone subset analysis has been conducted, but the evolocumab data provide the closest available proxy.

ODYSSEY OUTCOMES: The Key Safety Database

ODYSSEY OUTCOMES enrolled 18,924 adults with acute coronary syndrome within the prior 1 to 12 months, all on maximally tolerated statin therapy, randomized to alirocumab 75 to 150 mg subcutaneously every 2 weeks or matching placebo 4. Median follow-up was 2.8 years.

Primary and Safety Outcomes

The primary composite endpoint (MACE: coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) occurred in 9.5% of alirocumab patients versus 11.1% of placebo patients, a relative risk reduction of 15% (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) 4. The pre-specified safety analysis captured injection-site reactions (3.8% alirocumab vs. 2.1% placebo), myalgia, neurocognitive events, new-onset diabetes, and ophthalmologic events. Sexual dysfunction did not appear as a statistically notable adverse event in either arm.

What the Safety Reporting Does and Does Not Tell Us

Spontaneous adverse-event reporting in cardiovascular outcome trials systematically under-captures sexual dysfunction 11. Patients rarely volunteer this complaint unless asked directly on a validated instrument such as the International Index of Erectile Function (IIEF) or the Female Sexual Function Index (FSFI). ODYSSEY OUTCOMES did not administer either instrument. The absence of a reported signal therefore reflects the absence of active surveillance, not necessarily the absence of any effect.

Subgroup Data Relevant to Hormonal Endpoints

A pre-specified subgroup analysis published alongside the main ODYSSEY OUTCOMES paper examined all-cause mortality benefit in patients achieving LDL-C <25 mg/dL 4. This very-low-LDL-C group (approximately 30% of the alirocumab arm) showed the largest absolute mortality benefit and no disproportionate safety signal in any organ-system category. If steroidogenic depletion were clinically meaningful, this subgroup would be the place to find it.

Statin Co-Administration: Separating the Signals

Nearly every patient in ODYSSEY OUTCOMES was taking high-intensity statin therapy, most commonly rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg 4. Statins reduce intracellular mevalonate, which is upstream of both cholesterol and a family of isoprenoids that regulate steroidogenic enzyme activity 12.

Statin-Associated Sexual Dysfunction: What We Know

A 2010 cross-sectional study (N=3,484) published in the Journal of Sexual Medicine found that statin use was associated with modestly lower testosterone levels in men (mean difference approximately 0.3 nmol/L) 13. A 2014 Cochrane review of statin adverse effects concluded that the evidence for statin-induced sexual dysfunction was insufficient to draw firm conclusions 14. The clinical importance is that the statin confounder is present in virtually every alirocumab patient.

Disentangling Alirocumab's Contribution

Because randomization in ODYSSEY OUTCOMES placed equal numbers of statin-treated patients into alirocumab and placebo arms, any differential sexual-dysfunction signal would still be attributable to alirocumab. No such differential signal was identified. The practical implication for clinicians: if a patient on statin plus alirocumab reports new sexual dysfunction, the statin or underlying vascular disease is a more likely contributor than the PCSK9 inhibitor.

Endothelial Function and Sexual Health

Erectile function depends on nitric oxide-mediated penile arterial vasodilation 15. Cardiovascular disease impairs this pathway. Alirocumab's LDL-C reduction could theoretically improve endothelial function and thereby support rather than harm erectile performance. A 2017 study in patients with heterozygous familial hypercholesterolemia showed that PCSK9 inhibition (evolocumab, 140 mg every 2 weeks for 52 weeks) improved brachial artery flow-mediated dilation by 1.4 percentage points compared with placebo (P<0.05) 16. No penile artery study using alirocumab has been published, but the same endothelial mechanism applies.

Sex-Specific Considerations

Men: Testosterone, Libido, and Erectile Function

Testosterone synthesis in Leydig cells depends on LDL receptor-mediated cholesterol uptake and intracellular cholesterol esterase activity 17. Theoretical risk exists. Available evidence, though limited to indirect comparators, does not support a clinically significant reduction. The FOURIER hormone subset (mentioned above) found no significant free testosterone change with evolocumab at LDL-C levels comparable to those achieved with alirocumab 10.

Men who develop new erectile dysfunction while on alirocumab should have morning total testosterone measured (normal range 300 to 1,000 ng/dL per the American Urological Association), along with fasting glucose, HbA1c, and a review of all other medications 18.

Women: Estradiol, Menstrual Cycle, and Libido

Ovarian granulosa cells require LDL-derived cholesterol for estradiol synthesis via aromatase 19. No alirocumab-specific data on menstrual cycle regularity, estradiol levels, or female sexual function exist in the published literature as of mid-2025. The ODYSSEY OUTCOMES cohort was 75% male, limiting generalizability to women 4. Women who develop new sexual complaints, menstrual irregularity, or vaginal dryness while on alirocumab should have FSH, LH, estradiol, and free testosterone assessed before attributing symptoms to the drug.

Postmenopausal Women

In postmenopausal women, adrenal androgens (androstenedione, DHEA) provide the main substrate for peripheral estrogen synthesis. The Norata 2017 data suggesting slightly higher adrenal androgen levels in PCSK9 loss-of-function carriers is reassuring for this population, though the clinical magnitude is small 7.

Current Guideline Positions

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol does not list sexual dysfunction as a recognized adverse effect of PCSK9 inhibitors 20. The guideline states: "PCSK9 inhibitors are generally well tolerated, with injection-site reactions being the most common adverse effect" 20.

The 2019 European Society of Cardiology / European Atherosclerosis Society guidelines on dyslipidemia similarly do not list sexual dysfunction in the PCSK9 inhibitor safety profile, though both guidelines acknowledge that very-low LDL-C targets require ongoing post-marketing surveillance 21.

A practical clinical decision framework for managing a patient who reports sexual dysfunction while on alirocumab:

1. Confirm the timeline: did symptoms begin before or after alirocumab initiation?
2. Assess the statin: has the statin dose or type changed recently?
3. Check vascular risk: poorly controlled hypertension, diabetes, and smoking are the leading causes of erectile dysfunction in the cardiovascular population 15.
4. Measure hormones: morning total and free testosterone (men), estradiol and FSH (women), SHBG, and prolactin.
5. Review the full medication list: beta-blockers, spironolactone, and SSRIs are common co-prescriptions with known sexual side-effect profiles 22.
6. Do not discontinue alirocumab empirically without completing steps 1 through 5 in a patient with established ASCVD.

Neurocognitive and Mood Pathways That Intersect With Libido

Cholesterol is a structural component of myelin and synaptic membranes 23. Early case reports with statin therapy raised concerns about mood changes, and theoretically very-low LDL-C could affect central serotonergic or dopaminergic signaling pathways relevant to sexual desire. ODYSSEY OUTCOMES tracked neurocognitive adverse events prospectively; the alirocumab arm showed no excess of neurocognitive events vs. Placebo (1.2% vs. 1.5%, P=not significant) 4. The EBBINGHAUS cognitive substudy of evolocumab (N=1,204, median 19 months) found no difference on the Cambridge Neuropsychological Test Automated Battery, providing mechanistic class-level reassurance 24.

Mood and libido are closely linked. Depressive symptoms reduce sexual desire independently of hormonal status 25. Because patients with established ASCVD have a roughly 20 to 25% prevalence of comorbid depression, mood should be screened (PHQ-9) whenever sexual dysfunction is reported in this population 26.

Post-Marketing Surveillance and Real-World Signal

The FDA Adverse Event Reporting System (FAERS) is a spontaneous reporting database and is not designed for incidence calculations. As of the most recent publicly available FAERS data, sexual dysfunction terms (erectile dysfunction, decreased libido, anorgasmia) do not appear among the top 50 most-frequently reported adverse events for alirocumab 27. This absence is consistent with the clinical trial data, though spontaneous reporting bias means rare events may be missed.

The alirocumab prescribing label (Sanofi/Regeneron, revised 2023) lists the following adverse reactions occurring in greater than or equal to 2% of patients and more common than placebo: nasopharyngitis (11.3% vs. 11.1%), injection-site reactions (7.2% vs. 5.1%), influenza (5.7% vs. 4.5%), urinary tract infection (4.8% vs. 4.2%), diarrhea (4.7% vs. 4.3%), bronchitis (4.3% vs. 4.2%), myalgia (4.2% vs. 3.4%), and muscle spasms (3.3% vs. 2.7%) 28. Sexual dysfunction does not appear on this list.

Practical Counseling Points for Patients

Patients starting alirocumab should understand three things clearly.

First, the drug's cardiovascular benefit is well established. ODYSSEY OUTCOMES showed an absolute risk reduction of 1.6 percentage points in MACE over 2.8 years in a post-ACS population already on statin therapy 4. That translates to a number needed to treat of approximately 63 to prevent one MACE event.

Second, no prospective trial has administered validated sexual-function questionnaires to alirocumab-treated patients. Absence of evidence is not evidence of absence. Patients who notice any change in sexual function after starting the drug should report it to their prescriber rather than stopping the injection on their own.

Third, the most common drivers of sexual dysfunction in the PCSK9-inhibitor patient population are the underlying cardiovascular disease, co-administered medications (especially beta-blockers and certain antidepressants), and any comorbid metabolic dysfunction such as type 2 diabetes 15 29. Addressing these is the first clinical priority.